Burns J E, Baird M C, Clark L J, Burns P A, Edington K, Chapman C, Mitchell R, Robertson G, Soutar D, Parkinson E K
Cancer Research Campaign, Beatson Institute for Cancer Research, Garscube Estate, Bearsden, Glasgow, UK.
Br J Cancer. 1993 Jun;67(6):1274-84. doi: 10.1038/bjc.1993.238.
Using immunocytochemical and Western blotting techniques we have demonstrated the presence of abnormally high levels of p53 protein in 8/24 (33%) of human squamous cell carcinomas (SCC) and 9/18 (50%) of SCC cell lines. There was a correlation between the immunocytochemical results obtained with eight SCC samples and their corresponding cell lines. Direct sequencing of PCR-amplified, reverse transcribed, p53 mRNA confirmed the expression of point mutations in six of the positive cell lines and detected in-frame deletions in two others. We also detected two stop mutations and three out-of-frame deletions in five lines which did not express elevated levels of p53 protein. Several of the mutations found in SCC of the tongue (3/7) were in a region (codons 144-166) previously identified as being a p53 mutational hot spot in non-small cell lung tumours (Mitsudomi et al., 1992). In 11/13 cases only the mutant alleles were expressed suggesting loss or reduced expression of the wild type alleles in these cases. Six of the mutations were also detected in the SCCs from which the lines were derived, strongly suggesting that the mutations occurred, and were selected, in vivo. The 12th mutation GTG-->GGG (valine-->glycine) at codon 216 was expressed in line SCC-12 clone B along with an apparently normal p53 allele and is to our knowledge a novel mutation. Line BICR-19 also expressed a normal p53 allele in addition to one where exon 10 was deleted. Additionally 15 of the SCC lines (including all of those which did not show elevated p53 protein levels) were screened for the presence of human papillomavirus types 16 and 18 and were found to be negative. These results are discussed in relation to the pathogenesis of SCC and the immortalisation of human keratinocytes in vitro.
我们运用免疫细胞化学和蛋白质印迹技术,证实在24例人类鳞状细胞癌(SCC)中有8例(33%)以及18株SCC细胞系中有9株(50%)存在异常高水平的p53蛋白。用8个SCC样本及其相应细胞系获得的免疫细胞化学结果之间存在相关性。对PCR扩增、逆转录的p53 mRNA进行直接测序,证实6株阳性细胞系中有点突变表达,另外2株检测到框内缺失。我们还在5株未表达升高水平p53蛋白的细胞系中检测到2个终止突变和3个框外缺失。在舌部SCC(7例中的3例)中发现的几个突变位于先前确定为非小细胞肺癌p53突变热点的区域(密码子144 - 166)(Mitsudomi等人,1992年)。在13例中的11例中,仅表达了突变等位基因,表明在这些病例中野生型等位基因缺失或表达减少。在衍生出细胞系的SCC中也检测到6个突变,强烈表明这些突变是在体内发生并被选择的。密码子216处的第12个突变GTG→GGG(缬氨酸→甘氨酸)在细胞系SCC - 12克隆B中与一个明显正常的p53等位基因一起表达,据我们所知这是一个新突变。细胞系BICR - 19除了一个缺失外显子10的等位基因外,还表达一个正常的p53等位基因。此外,对15株SCC细胞系(包括所有未显示p53蛋白水平升高的细胞系)进行了16型和18型人乳头瘤病毒检测,结果均为阴性。结合SCC的发病机制和人角质形成细胞在体外的永生化对这些结果进行了讨论。